Skip to main content
. 2013 Dec 17;8:288. doi: 10.1186/1748-717X-8-288

Table 4.

Baseline clinical characteristics of first 132consecutive study patients from each technique group

Characteristics
 Total sample
 Implant technique
 P value
 
  
 PP
 IoP
  
  (n =264) (n =132) (n = 132)  
Age, years
  
  
  
  
      Mean (SD)
 67.7 (5.8)
 67.9 (6.0)
 67.4 (5.7)
  
      Median
 68.0
 68.0
 68.0
  
      Range
 50.0–83.0
 50.0–83.0
 52.0–78.0
  
      95% CI
 66.9–68.4
 66.9–68.9
 66.4–68.4
 0.6*
PSA, ng/ml
  
  
  
  
      Mean (SD)
 8.2 (3.4)
 8.6 (3.7)
 7.8 (3.1)
  
      Median
 7.6
 7.6
 7.5
  
      Range
 0.7–20.0
 0.7–20.0
 0.8–17.0
  
      95% CI
 7.8–8.6
 7.9–9.2
 7.3–8.3
 0.1*
PSA, n (%)
  
  
  
  
      ≤ 10
 201 (76.1)
 94 (71.2)
 107 (81.1)
  
      > 10
 63 (23.9)
 38 (28.8)
 25 (18.9)
 0.06**
Gleason score,
  
  
  
  
      Mean (SD)
 5.5 (0.9)
 5.3 (0.9)
 5.7 (0.8)
  
      Median
 6.0
 5.0
 6.0
  
      Range
 1.0–7.0
 2.0–7.0
 1.0–7.0
  
      95% CI
 5.4–5.6
 5.1–5.4
 5.6–5.8
 <0.001*
Gleason score < 7, n (%)
 248 (93.9)
 128 (97)
 120 (90.9)
 0.07**
Clinical stage, n (%)
  
  
  
  
      T1-T2a
 225 (90.7)
 113 (89.0)
 112 (92.6)
  
      > T2a
 23 (9.3)
 14 (11.0)
 9 (7.4)
 0.3**
ADT, n (%)
 112 (42.4)
 54 (40.9)
 58 (43.9)
 0.6**
EBRT, n (%)
 16 (6.1)
 4 (3)
 12 (9.1)
 0.07**
Follow-up, months
  
  
  
  
      Mean (SD)
 83.3(39.6)
 80.5 (43.5)
 86.2 (35.2)
  
      Median
 84.0
 83.0
 95.5
  
      Range
 3.0–155.0
 3.0–155.0
 7.0–132.0
  
      95% CI 78.5–88.1 72.9–87.9 80.2–92.3 0.4*

* Mann–Whitney test; ** Chi-square test.

PP, Preplanning; IoP, Intraoperative planning; PSA, Prostate-specific antigen ADT, Androgen deprivation therapy; EBRT, External beam radiation.